益脑康胶囊的质量控制

目的:建立益脑康胶囊的质量控制方法。方法:采用薄层色谱法定性鉴别方中主药黄芪、西洋参、三七;采用高效液相色谱-蒸发光散射法测定主药黄芪中黄芪甲苷的含量。结果:薄层定性鉴别条件适合,斑点清晰,重复性好;黄芪甲苷检测线性范围为2.15～10.75μg(r=0.9996),平均回收率为100.33%,RSD为2.62%。结论:质量控制方法简便、准确,精密度高,可以有效地控制益脑康胶囊制剂的质量。     

浮小麦质量控制探讨

目的：修订完善舒胸胶囊原标准中鉴别及含量测定方法。方法：采用薄层色谱法鉴别三七、红花及高效液相色谱法测定三七中人参皂苷Rg1,Rb1和三七皂苷R。的总量。结果：三七、红花薄层斑点清晰;人参皂苷Rg1,Rb1,三七皂苷R1分别在0．442～11．050μg（r=0．9998）、0．344-8．600μg（r=0．9999）、0．208-5．200μg（r=0．9994）范围内线性关系良好,平均回收率分别为98．97％（RSD为1．4％）、99．57％（RSD为1．8％）、98．58％（RSD为2．2％）。结论：所建方法简便、准确,可用于舒胸胶囊的质量控制。     

胃康灵胶囊质量标准研究

目的建立胃康灵胶囊质量标准.方法采用薄层色谱法对胶囊中的三七、白芍、延胡索进行定性鉴别;采用反相高效液相色谱法测定胶囊中芍药苷的含量.结果在薄层色谱中均能检出三七、白芍、延胡索;芍药苷在0.01～0.05 mg/ml范围内呈良好线性关系(r=0.9991),平均回收率为98.56%,RSD=2.61%(n=5).结论该法灵敏、准确,能有效地控制胃康宁胶囊的质量.     

痔炎平胶囊的质量控制方法

目的:建立痔炎平胶囊质量控制标准.方法:采用薄层扫描法对该药中盐酸小檗碱进行含量测定;采用薄层色谱法对痔炎平胶囊中槐角、五倍子、三七进行了鉴别.结果:在TLC色谱图中可检出槐角、五倍子、三七,斑点清晰、分离效果好,盐酸小檗碱在0.20～1.00g浓度范围内呈良好的线性关系(R=0.9985),平均回收率为98.86%,RSD=1.06%.结论:所用方法新颖、准确.     

胃康灵胶囊质量标准研究

目的 建立胃康灵胶囊质量标准。方法 采用薄层色谱法对胶囊中的三七、白芍、延胡索进行定性鉴别;采用反相高效液相色谱法测定胶囊中芍药苷的含量。结果 在薄层色谱中均能检出三七、白芍、延胡索;芍药苷在0.01～0.05mg/ml范围内呈良好线性关系(r=0.9991),平均回收率为98.56％,RSD=2.61％(n=5)。结论 该法灵敏、准确,能有效地控制胃康宁胶囊的质量。     

脑脉醒神胶囊的薄层鉴别研究

目的:建立脑脉醒神胶囊的薄层鉴别方法,为其质量标准的制定提供依据.方法:采用薄层色谱法鉴别脑脉醒神胶囊中的大黄、黄芩、枳实、丹参、三七.结果:脑脉醒神胶囊中的大黄、黄芩、枳实、丹参、三七和对照药材薄层色谱主斑点位置一致;定性鉴别斑点圆整,分离度好,易于区别.结论:建立的方法简便、灵敏、准确、专属性强,可作为脑脉醒神胶囊的质量控制方法之一.     

溃疡灵胶囊质量标准研究

目的建立溃疡灵胶囊的质量控制标准。方法以薄层色谱法鉴别处方中的儿茶和浙贝母,以反相高效液相色谱法测定三七中三七皂苷R1的含量。结果溃疡灵胶囊中儿茶和浙贝母的薄层色谱斑点清晰;三七皂苷R1进样量线性范围是0．04228～2．114μg（n=7,r=0．9981）,平均回收率为102．56％,RSD=0．30％（n=6）。结论方法专属性强、灵敏度高、重现性好、操作简便,适合于溃疡灵胶囊的质量控制。     

复方硒酸酯多糖胶囊质量控制标准的研究

目的 :研究复方硒酸酯多糖胶囊的质控标准。方法 :采用薄层色谱法鉴别复方硒酸酯多糖胶囊中黄芪、白花蛇舌草 ,用荧光分光光度法测定硒的含量。结果 :硒的线性浓度范围为0～0 5μg/ml,平均回收率为100 4% ,RSD=0 91 %。结论 :本方法操作简便,结果准确 ,可用于复方硒酸酯多糖胶囊的质量控制。     

延肾胶囊的制备及质量标准研究

目的:制备延肾胶囊并建立其质量标准。方法:以薄层色谱法鉴别延肾胶囊中的三七、大黄、黄芪;以薄层双波长反射式锯齿扫描法测定大黄有效成分大黄素的含量:展开剂为正己烷-乙酸乙酯-甲酸(20∶10∶0.5);检测波长为437nm,参比波长为700nm,散射参数为3.0;狭缝为0.4mm×0.4mm。结果:三七、大黄、黄芪的薄层斑点清晰,分离良好。大黄素点样浓度在0.5~2.5μg·mL-1范围内与斑点峰面积积分值呈良好的线性关系(r=0.9971);平均加样回收率为95.06%,RSD=1.44%(n=5)。结论:制备方法简便、可行;所建标准可用于该制剂的质量控制。     

脑脉通胶囊的制备与临床应用

目的制备脑脉通胶囊,建立质量控制方法,并观察其临床疗效。方法采用薄层色谱法对处方药物进行定性,采用总浸出物控制制剂含量。并进行临床观察。结果脑脉通胶囊总浸出物含量35.0%;临床有效率96.1%。结论脑脉通胶囊制备工艺合理,检测方法可行,质量可靠,疗效确切。     

Nachweis einiger Heilmittel in der Kniegelenksynovialflüssigkeit

Zusammenfassung Mittels Gaschromatographie und Dünschichtchromatographie wiesen die Autoren 11 Substanzen nach, welche durch Injektion oder nach Verabreichung per os in die Kniegelenksynovialflüssigkeit eindrangen. In ihrer Aufstellung konnten sie eine direkte Beziehung zwischen Struktur sowie chemischphysikalischen Eigenschaften der Substanz und ihrer Fähigkeit, aus dem Blut in die Kniegelenksynovialflüssigkeit einzudringen, nicht nachweisen, außer der Tatsache, daß Substanzen mit starker Affinität zu Eiweißstoffen erst in höheren Dosen nachweisbar waren.     

Synthesis,Cytotoxicity and Antileishmanial Activity of Some N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines

We report herein the condensation of 4,7-dichloroquinoline (1) with tryptamine (2) and D-tryptophan methyl ester (3) . Hydrolysis of the methyl ester adduct (5) yielded the free acid (6) . The compounds were evaluated in vitro for activity against four different species of Leishmania promastigote forms and for cytotoxic activity against Kb and Vero cells. Compound (5) showed good activity against the Leishmania species tested, while all three compounds displayed moderate activity in both Kb and Vero cells.     

Emerging drugs for epilepsy

Epilepsy affects ≤ 1% of the world's population. Antiepileptic drugs (AEDs) are the mainstay of treatment, although more than a third of patients are not rendered seizure free with existing medications. Uncontrolled epilepsy is associated with increased mortality and physical injuries, and a range of psychosocial morbidities, posing a substantial economic burden on individuals and society. Limitations of the present AEDs include suboptimal efficacy and their association with a host of adverse reactions. Continued efforts are being made in drug development to overcome these shortcomings employing a range of strategies, including modification of the structure of existing drugs, targeting novel molecular substrates and non-mechanism-based drug screening of compounds in traditional and newer animal models. This article reviews the need for new treatments and discusses some of the emerging compounds that have entered clinical development. The ultimate goal is to develop novel agents that can prevent the occurrence of seizures and the progression of epilepsy in at risk individuals.     

盐酸达泊西汀中甲磺酸甲酯、甲磺酸乙酯及甲磺酸异丙酯的顶空毛细管GC-ECD法测定

建立了衍生化顶空毛细管气相色谱-电子捕获检测器(ECD)法测定盐酸达泊西汀中的甲磺酸甲酯(MMS)、甲磺酸乙酯(EMS)和甲磺酸异丙酯(IMS).应用碘化钠衍生技术,使用PW-5毛细管柱,载气为氮气,ECD检测,程序升温.MMS、EMS和IMS分别在0.03～0.30、0.05～0.50和0.05～0.50 μg/ml浓度范围内线性关系良好,平均回收率分别为63.5％、100.3％和96.2％,最低检测限分别为0.30、0.50和0.50 ng/ml.     

Lung disease and PKCs

The lung offers a rich opportunity for development of therapeutic strategies focused on isozymes of protein kinase C (PKCs). PKCs are important in many cellular responses in the lung, and existing therapies for pulmonary disorders are inadequate. The lung poses unique challenges as it interfaces with air and blood, contains a pulmonary and systemic circulation, and consists of many cell types. Key structures are bronchial and pulmonary vessels, branching airways, and distal air sacs defined by alveolar walls containing capillaries and interstitial space. The cellular composition of each vessel, airway, and alveolar wall is heterogeneous. Injurious environmental stimuli signal through PKCs and cause a variety of disorders. Edema formation and pulmonary hypertension (PHTN) result from derangements in endothelial, smooth muscle (SM), and/or adventitial fibroblast cell phenotype. Asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are characterized by distinctive pathological changes in airway epithelial, SM, and mucous-generating cells. Acute and chronic pneumonitis and fibrosis occur in the alveolar space and interstitium with type 2 pneumocytes and interstitial fibroblasts/myofibroblasts playing a prominent role. At each site, inflammatory, immune, and vascular progenitor cells contribute to the injury and repair process. Many strategies have been used to investigate PKCs in lung injury. Isolated organ preparations and whole animal studies are powerful approaches especially when genetically engineered mice are used. More analysis of PKC isozymes in normal and diseased human lung tissue and cells is needed to complement this work. Since opposing or counter-regulatory effects of selected PKCs in the same cell or tissue have been found, it may be desirable to target more than one PKC isozyme and potentially in different directions. Because multiple signaling pathways contribute to the key cellular responses important in lung biology, therapeutic strategies targeting PKCs may be more effective if combined with inhibitors of other pathways for additive or synergistic effect. Mechanisms that regulate PKC activity, including phosphorylation and interaction with isozyme-specific binding proteins, are also potential therapeutic targets. Key isotypes of PKC involved in lung pathophysiology are summarized and current and evolving therapeutic approaches to target them are identified.